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remitting conditions and chronic inflammation in the intestine. 3, 4 Development and/or pathogenesis of IBD is considered to be an inadequate immune response to luminal contents. New medical therapies have been rapidly introduced for the treatment of IBD, such as biological therapy, immunomodulators, and leukocyte apheresis therapy, among others. 5, 6 Surgical treatments corresponding to these changes are also needed. In contrast, a diverticulum is a small outpouching from the intestinal lumen due mostly to mucosal herniation through the wall at sites of vascular perforation. 2, 7 Diverticulitis is inflammation or infection of the diverticulum, which occurs mostly in the colon. In Japan, diverticulosis is increasing because of a widespread elderly population and changing lifestyle. Approximately 80%
of patients with diverticulosis remain asymptomatic, and the other 20% of patients develop diverticulitis, requiring medical treatment. 
| INFL AMMATORY BOWEL D IS E A S E
Inflammatory bowel disease is a chronic disease that causes unexplained inflammation in the gastrointestinal tract and comprises UC and CD. The number of patients is increasing globally, as well as in Japan. 8, 9 Abnormalities in the gut immune system are thought to be highly involved in the development of IBD, but the exact pathogenic mechanism is unclear. 2, 8 As both UC and CD often occur in young people and require long-term treatment, they not only lower the quality of life (QOL), but hinder social activities, such as schooling, work, marriage, and childbirth. In addition, new problems, such as inflammation-related carcinogenesis, have emerged with an increase in long-term cases. increased from 20% to 40% in CD patients, and from 5% to 16% in UC patients. 11 Kimura et al 12 showed that in 2011, Japanese patients treated with a biological preoperatively increased dramatically, and that in 2013, 41% of UC patients who underwent surgery had received biological treatment. Japanese nationwide cohort study also showed the rate of administration of anti-tumor necrosis factor (TNF) increased from 0.3% in 2007 to 43% in 2017 among UC patients who underwent restorative proctocolectomy. 13 Given the continuous emergence of biological therapies used more frequently in severe IBD, we are in a new era of biological therapy, including anti-TNFα, anti-interleukin (IL)-12/23p40, anti-integrin α4β7, and Janus kinase inhibitor, which will likely continue for some time. Assessment of variability in real-world practice is essential to optimize the timing of initial therapy and surgery for IBD patients. According to a study of regional differences in the treatment of IBD after 2006, 66% of CD and 28% of UC patients in the USA commonly used biological therapy, compared to 19% of CD and 0% of UC patients in China.
No differences were seen in the proportion of patients undergoing early surgery.
14 With regard to surgical treatment, preoperative conditions in IBD are often immunosuppressive or patients are undernourished, and different from other bowel diseases, such as colorectal cancer.
This section outlines points to be aware of in the surgical treatment of UC and CD.
| Surgical treatment and biological therapy
Several reports, including randomized controlled trials, assessed preoperative treatment and surgical rates. The Active Ulcerative
Colitis Trial (ACT) reported the efficacy of infliximab for induction and maintenance therapy and the cumulative incidence of colectomy in 728 patients with moderate-to-severe active UC. Patients receiving infliximab had a decreased Mayo score with decreased rectal bleeding compared to placebo patients. At 54 weeks of follow up, the colectomy rate was 10% in the infliximab group and 17% in the placebo group; which means the absolute risk of colectomy decreased by 7%. 15, 16 Another study evaluated the short-and longterm efficacy of infliximab in 45 patients with steroid-resistant UC (24 infliximab and 21 placebo); 29% in the infliximab group and 67%
in the placebo group underwent colectomy within 3 months, and 50% in the infliximab group and 76% in the placebo group within 3 years. No patient death was reported. Patients who had endoscopic remission within 3 months did not require colectomy, even after 3 years. The main benefit of infliximab occurred within the first 3 months, and early mucosal healing reduced the risk of subsequent colectomy. 17, 18 The CONSTRUCT study showed the efficacy of infliximab and cyclosporine in 270 patients with steroid-resistant UC. The colectomy rate within 3 years was 41% in the infliximab group and 48% in the cyclosporine group, and no significant differences were observed between the two groups. 19 
| Postoperative complications
Crohn's disease cannot be completely cured by surgery, and redo surgery for recurrence is often necessary. For efficient prevention of postoperative recurrence, it is essential to identify high-risk cases of recurrence. The relationship between preoperative biological therapy and postoperative complications has been studied, but is still con- Another case-matched analysis showed that exposure to preoperative vedolizumab was not associated with increased morbidity, but the majority of patients had an ostomy. 35 The impact of biologicals on postoperative complications is still controversial. Summary of previous reports is shown in Table 1 . 23, 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Large prospective studies are required to draw conclusions.
Inflammatory bowel disease is associated with a 1.5-to 3-fold in- 
| Positioning of surgical treatment
The LIR!C trial evaluated the cost-effectiveness of laparoscopic ileocecal resection compared to infliximab in CD patients who failed more than 3 months of conventional immunomodulator or steroid therapy without signs of critical strictures. A total of 143 patients were included in this randomized trial, and total direct healthcare and social costs were lower in the resection group than in the infliximab group. Laparoscopic ileocecal resection is a cost-effective treatment compared to infliximab. 46 Murthy et al evaluated the impact of infliximab on hospitalization, surgery rates, and costs in IBD patients living in Ontario, Canada. The introduction of infliximab did not result in a significant reduction in hospitalization and surgery rates among CD patients, whereas the hospitalization rates declined substantially among UC patients. They reported a threefold increase in drug costs for CD patients following the introduction of infliximab, but no significant change in UC patients. 47 The CONSTRUCT study showed the use of cyclosporine led to lower total costs compared to infliximab in UC patients.
Nevertheless, no significant difference was found between these drugs regarding clinical effectiveness, colectomy rates, incidence of side-effects, or mortality 1-3 years post-treatment. However, participants were more positive about infliximab than cyclosporine, and nurses disliked the i.v. cyclosporine.
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In recent years, enhanced recovery after surgery (ERAS) has been shown to reduce length of hospital stay, complications, and costs after colorectal surgery, but the effect on IBD has been unclear. Liska et al reported an improvement in outcomes using ERAS in 671 IBD patients. Implementation of ERAS for IBD patients resulted in a decrease in length of hospital stay and costs without any increase in complications and readmissions. 48 Robotic surgery for IBD has gradually spread, but the hybrid approach would currently be optimal for complicated cases. Mizushima et al 50 reported that single-incision laparoscopic surgery can be carried out safely in patients with stricturing or penetrating CD. In UC patients undergoing ileal pouch-anal anastomosis, the 30-day postoperative complication rate was comparable to laparoscopic surgery. 51 The use of open, laparoscopic, and robotic surgery should be balanced with cost-effectiveness and postoperative outcomes.
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TA B L E 1 Impact of biologicals on postoperative complications
| Bariatric surgery for IBD patients
In recent years, the relationship between obesity and IBD has attracted attention. The use of robotic surgery for colorectal diseases has been reported in recent years. Ogilvie et al studied elective sigmoidectomy for diverticulitis, comparing laparoscopic and robotic surgery. Sixtynine robotic cases were propensity-matched from a group of 222 laparoscopic cases; they found no difference in postoperative pain and length of stay, but total hospital costs were $15 000 higher for robotic surgery. 58 Robotic and laparoscopic surgery were also compared in the elective management of left side diverticulitis. Robotic surgery was associated with shorter hospital stay (3.89 vs 4.75 days), lower conversion rate (7.5% vs 14.3%), and longer operative time (219.2 vs 188.8 minutes) than laparoscopic surgery. 59 Cassini et al evaluated the effectiveness, potential benefits, and short-term outcomes of 64 patients undergoing robotic surgery compared to 92 patients undergoing laparoscopic surgery for complicated diverticulitis. No conversions occurred in the robotic group compared to a 6.5% conversion rate in the laparoscopic group. Operative time, blood loss, hospital stay, and postoperative morbidity were not significantly different between the two groups. 60 Raskin et al 61 showed
| Surgical approach
that the robotic-assisted approach was associated with fewer con- and a longer time from symptom onset (over 2 days) to surgery were prognostic factors for postoperative mortality. 62 Therefore, careful patient selections are necessary for laparoscopic surgery. Open surgery should be considered in cases with long duration from onset, cases with shock, cases with serious comorbidities, and/or cases with pan-peritonitis.
| Surgical procedure
Hartmann's operation has been carried out conventionally for complicated diverticulitis. The Hartmann operation has the challenge of stoma reversal and 30%-40% of stoma cannot be closed. 63, 64 Primary resection and anastomosis, and laparoscopic lavage are widespread as an alternative surgery. The LADIES trial assessed outcomes after Hartmann's procedure versus sigmoidectomy and primary anastomosis with or without protective ileostomy in 133 patients with severe sigmoid diverticulitis (Hinchey III or IV disease) aged <85 years. Twelve-month stoma-free survival was significantly better in patients with primary anastomosis, and no significant differences were observed in short-term morbidity and mortality between the two procedures. 65 Several studies have reported that primary anastomosis was similar to Hartmann's operation regarding major postoperative complications, mortality, and readmission rate. 66, 67 However, Cauley et al 68 reported that complication rates and in-hospital mortality rates for primary anastomosis with diversion were higher than those for Hartmann's procedure. According to a review by Cirocchi et al, there is no significant difference in mortality and overall morbidity between primary anastomosis and Hartman's operation for perforated sigmoid diverticulitis with generalized peritonitis, although postoperative intra-abdominal abscesses are fewer after primary anastomosis. Permanent stoma rates were not significantly different in these groups. 69 Goldstone et al reported that postoperative mortality was twofold greater when general surgeons carried out a primary anastomosis compared to Hartmann's operation (7.4% vs 15%). Primary anastomosis by general surgeons was associated with postoperative complications and reoperation, whereas colorectal board certification was associated with decreased mortality. 70 Several studies of laparoscopic lavage as an alternative procedure have been reported in recent years. 71 The DILALA trial re- The authors reported no difference in readmissions or mortality between these procedures. 72 Penna et al also studied clinical outcomes after laparoscopic lavage or colonic resection in 589 patients with purulent diverticulitis. They reported no significant differences in mortality, 30-day reoperation, or unplanned readmissions. The laparoscopic lavage group had more intra-abdominal abscesses, peritonitis, and long-term emergency reoperations, but this group had shorter operative time, fewer cardiac complications, fewer wound infections, and shorter hospital stay; 14% of patients in this group required a stoma. 73 However, some reports found an association between laparoscopic lavage and increased morbidity, whereas laparoscopic lavage and other surgical procedures had comparable rates of early reoperation and postoperative mortality. 74 Sneiders et al reported outcomes in patients treated with laparoscopic peritoneal lavage without sigmoidectomy for perforated diverticulitis with purulent peritonitis. More than 30% required additional surgery and readmissions; 31% of patients initially treated successfully had recurrent diverticulitis or other complications, and 22% of these patients eventually had a sigmoidectomy within 90 days. 75 After Hartmann operation for diverticulitis requiring surgery, optimal timing of subsequent colostomy reversal remains unknown.
Resio et al reported that early reversal (45-110 days) is associated with patient age (≤60 years), ethnicity (Caucasian), and private insurance.
Prolonged length of stay and 90-day readmissions were significantly increased with late reversal, whereas mortality, transfusion, ileus, and major complications were not significantly associated with reversal timing. 76 Open surgery, preoperative steroid use, and disease-related factors were involved in ileostomy creation after primary anastomosis. 77 Surgery for uncomplicated diverticulitis was also reported. Luu et al reported that both laparoscopic diverticulectomy and non-operative treatment were safe and effective in patients with uncomplicated right-sided colonic diverticulitis. Laparoscopic diverticulectomy could be an option in a case with possible recurrence. 78 
| Postoperative complications and longterm outcomes
The DIRECT trial showed significantly better QOL (less pain, lower risk of new recurrences) at the 5-year follow up in patients who underwent elective sigmoidectomy compared to conservative treatment for recurring diverticulitis and/or ongoing complaints after an episode of diverticulitis. Forty-six percent of patients with conservative treatment required surgery as a result of severe ongoing complaints. 79 This trial also showed that elective sigmoidectomy is cost-effective compared to conservative treatment. short-term treatment failure, emergency surgery, or long-term surgery. Abscesses more than 3 cm were associated with shortterm treatment failure, and abscesses more than 5 cm were associated with the need for surgery. 83 After surgery for diverticulitis, patients with metabolic syndrome (BMI >30 kg/m 2 , hypertension, and DM) had more adverse events, such as reintubation, ventilator dependence more than 48 hours, myocardial infarction, and superficial or deep surgical site infections. Patients with metabolic syndrome also had longer recovery and higher rates of complications, readmissions, and mortality. 84 Bordeianou 
| CON CLUS IONS
In the present review, we updated advancements in the surgical treatment of IBD and diverticulitis based on recent findings. The prevalence of these diseases will increase in the future as already seen in developed countries. Although surgical technology, including robotic surgery, is rapidly progressing, surgeons need to carry out the most appropriate treatment to prevent unfavorable outcomes for patients. Not only colorectal surgeons, but also general surgeons, should always keep in touch with these novel ideas and concepts to improve the QOL of patients.
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